SOLANA BEACH, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand
Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 SOLANA BEACH, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
SOLANA BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the
EVERSANA to commercialize and distribute Gimoti in the U.S. EVERSANA to provide $5 million revolving credit facility upon FDA approval SOLANA BEACH, Calif. and CHICAGO , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
PDUFA Target Goal Date is June 19, 2020 SOLANA BEACH, Calif. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S.
SOLANA BEACH, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S.
SOLANA BEACH, Calif. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019 , it received notification from the Listing Qualifications Department of
SOLANA BEACH, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019 , it received notification from the Listing Qualifications Department of
Gimoti NDA resubmission on track for fourth quarter 2019 SOLANA BEACH, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third